Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600X PIK3CA H1047X Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus ovarian carcinoma predicted - sensitive detail...
TP53 I195* TP53 R248Q ReACp53 ovarian carcinoma sensitive detail...
TP53 Y234C ReACp53 ovarian carcinoma sensitive detail...
TP53 Y327L ReACp53 ovarian carcinoma sensitive detail...
TP53 inact mut ReACp53 ovarian carcinoma sensitive detail...
RAD51C R193* Rucaparib ovarian carcinoma predicted - sensitive detail...
RAD51C H192_R193delinsGG RAD51C R193* RAD51C R193L RAD51C R193W Rucaparib ovarian carcinoma predicted - resistant detail...
RAD51C R193L Rucaparib ovarian carcinoma resistant detail...
RAD51C R193W Rucaparib ovarian carcinoma resistant detail...
RAD51C H192_R193delinsGG Rucaparib ovarian carcinoma resistant detail...
RAD51C R193L Niraparib ovarian carcinoma resistant detail...
RAD51C R193W Niraparib ovarian carcinoma resistant detail...
RAD51C H192_R193delinsGG Niraparib ovarian carcinoma resistant detail...
RAD51C R193L Olaparib ovarian carcinoma resistant detail...
RAD51C R193W Olaparib ovarian carcinoma resistant detail...
RAD51C H192_R193delinsGG Olaparib ovarian carcinoma resistant detail...
RAD51C R193L Talazoparib ovarian carcinoma resistant detail...
RAD51C R193W Talazoparib ovarian carcinoma resistant detail...
RAD51C H192_R193delinsGG Talazoparib ovarian carcinoma resistant detail...
RAD51C R193W Veliparib ovarian carcinoma resistant detail...
RAD51C H192_R193delinsGG Veliparib ovarian carcinoma resistant detail...
RAD51D G258Sfs*50 Rucaparib ovarian carcinoma sensitive detail...
RAD51D S257_R259delinsK RAD51D G258Sfs*50 Rucaparib ovarian carcinoma predicted - resistant detail...
TP53 mutant Adavosertib ovarian carcinoma predicted - sensitive detail...
MSH6 negative Nivolumab ovarian carcinoma predicted - sensitive detail...
MLH1 negative Nivolumab ovarian carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00989651 Phase I Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01248962 Phase II Carboplatin Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer Completed USA 0
NCT01281514 Phase I Carboplatin + Everolimus + Pegylated liposomal doxorubicin Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed USA 0
NCT01504126 Phase I Propranolol Beta-Blocker / Ovarian Completed USA 0
NCT01543763 Phase I Panobinostat + Pazopanib Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Active, not recruiting USA 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | DNK | CAN 0
NCT01669798 Phase II Nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Completed USA 0
NCT01849874 Phase III Binimetinib A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Terminated USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS 0
NCT01936974 Phase II Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Terminated USA 0
NCT01940172 Phase I Conatumumab Birinapant Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer Completed USA 0
NCT01974765 Phase II Enzalutamide Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Completed USA 0
NCT02042430 Phase I Epacadostat INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02059265 Phase II Dasatinib Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Terminated USA 0
NCT02098343 Phase Ib/II Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Completed USA | SWE | NLD | GBR | FRA | ESP | DEU | BEL 0
NCT02101775 Phase II Gemcitabine Adavosertib + Gemcitabine Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA | CAN 1
NCT02101788 Phase II Topotecan Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Tamoxifen Trametinib Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting USA | GBR 0
NCT02121990 Phase I Bevacizumab + Cisplatin + Olaparib + Paclitaxel Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed USA 0
NCT02122185 Phase II Metformin Carboplatin + Docetaxel + Paclitaxel Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02166905 Phase Ib/II Poly ICLC Rasdegafusp alfa Epacadostat DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed USA 0
NCT02270372 Phase I Varlilumab ONT-10 Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer Completed USA 0
NCT02283658 Phase II Everolimus + Letrozole Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed USA 0
NCT02431559 Phase Ib/II Aldoxorubicin + Durvalumab + Motolimod A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated Completed USA | CHE 0
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Completed USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02459301 Phase I Monalizumab Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin Completed CAN 0
NCT02470585 Phase III Carboplatin Paclitaxel Veliparib Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA | POL | NZL | ISR | GBR | ESP | DNK | BRA | AUS 2
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Terminated USA 0
NCT02489006 Phase II Olaparib A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NZL | GBR | ESP | CAN 0
NCT02520115 Phase I Dexamethasone Valproic acid Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Completed USA 0
NCT02571725 Phase Ib/II Olaparib + Tremelimumab PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Active, not recruiting USA 0
NCT02608684 Phase II Cisplatin + Gemcitabine + Pembrolizumab A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer Completed USA 0
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Completed USA 0
NCT02659241 Phase I Adavosertib A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer Active, not recruiting USA 0
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed USA | NLD | ITA | ESP | DNK | CAN | BEL 0
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Completed USA 0
NCT02764333 Phase II Durvalumab + TPIV 200 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer Completed USA 0
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed USA 0
NCT02953457 Phase II Durvalumab + Olaparib + Tremelimumab Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Completed USA 0
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT03017131 Phase I Aldesleukin + Cyclophosphamide + Decitabine + Letetresgene autoleucel Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT03029403 Phase II Cyclophosphamide + Maveropepimut-S + Pembrolizumab Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting CAN 0
NCT03220932 Phase III Bevacizumab Cisplatin Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer (HIPOVA-01) Unknown status FRA 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03878849 Phase II E7449 Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP (PREDICT 2X-121) Active, not recruiting USA | GBR 0
NCT03924245 Phase Ib/II Entinostat Entinostat + Olaparib Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Terminated USA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04274426 Phase II Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA) Active, not recruiting DEU 0
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04498117 Phase III Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) Active, not recruiting USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG 5
NCT04735796 Phase I LM-102 Study of LM-102 in Subjects in Advanced Tumors Terminated USA 0
NCT04861181 FDA approved Niraparib NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) Recruiting FRA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Recruiting USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS 4
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Completed USA 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05163041 Phase Ib/II BT7480 BT7480 + Nivolumab Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression Recruiting USA | GBR 0
NCT05548296 Phase Ib/II Prexasertib Gemcitabine + Prexasertib A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05636111 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Recruiting USA 0
NCT05949424 FDA approved Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) Not yet recruiting NLD 0
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 2
NCT06216561 Phase I CEND-1 Intraperitoneal LSTA1 in CRS-HIPEC Withdrawn USA 0
NCT06264921 Phase I NKT3447 A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06444815 Phase I VET3-TGI Pembrolizumab + VET3-TGI A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) Recruiting USA 0